CTIS2023-508471-37-00进行中（未招募）1 期
A proof-of-concept study with NVDX3, an osteogenic implant of human allogenic origin, in the treatment of low grade degenerative lumbar spondylolisthesis by interbody spine fusion in adults.
ovadip Biosciences0 个研究点目标入组 10 人开始时间: 2023年11月21日最近更新:
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 10
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 至 64（—）
- 性别
- All
入选标准
- 未提供
排除标准
- 未提供
研究者
相似试验
进行中（未招募）
1 期
A first-in-human proof-of-concept study with NVDX3, an osteogenic implant of human allogenic origin, in the treatment of distal radius fractures in adults.Distal radius fracturesCTIS2023-508321-27-00ovadip Biosciences10
进行中（未招募）
1 期
Clinical study to evaluate the safety and preliminary efficacy of the autologous 3D osteogenic implant for the treatment of the children patients with congenital pseudarthrosis of the tibiacongenital pseudarthrosis of the tibia (CPT)EUCTR2022-001282-12-BEovadip Biosciences4
尚未招募
3 期
A Randomized, Open-label, Phase 3 Trial of Dato-DXd Plus Pembrolizumab vs Pembrolizumab Alone in Treatment-naïve Subjects with Advanced or Metastatic PD-L1 High (TPS >=50%) Non-small Cell Lung Cancer Without Actionable Genomic Alterations (TROPION-Lung08)lungcancer10029211Non-Small Cell Lung CancerNL-OMON55935Daiichi Sankyo, Inc.15
进行中（未招募）
1 期
Study of DS-1062a with or without Pembrolizumab in Advanced or Metastatic Non-small Cell Lung Cancer without Actionable Genomic AlterationsEUCTR2021-002555-10-GRDaiichi Sankyo, Inc.740
进行中（未招募）
1 期
Study of DS-1062a with or without Pembrolizumab in Advanced or Metastatic Non-small Cell Lung Cancer without Actionable Genomic AlterationsEUCTR2021-002555-10-ESDaiichi Sankyo, Inc.740